Pfizer (PFE) EVP Alexandre de Germay awarded 194,883 stock appreciation rights

Rhea-AI Filing Summary

de Germay Alexandre reported acquisition or exercise transactions in this Form 4 filing.

Pfizer Inc. Executive Vice President Alexandre de Germay received a grant of 194,883 stock appreciation rights on Pfizer common stock. These rights were awarded at no purchase price and are classified as a derivative security. According to the terms, the stock appreciation rights are subject to vesting requirements and will be settled in shares of Pfizer common stock on the fifth anniversary of the grant date.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider de Germay Alexandre

Role Executive Vice President

Type	Security	Shares	Price	Value
Grant/Award	Stock Appreciation Rights	194,883	$0.00	--

Holdings After Transaction: Stock Appreciation Rights — 194,883 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

de Germay Alexandre

(Last) (First) (Middle)

66 HUDSON BOULEVARD EAST

ATTN: CORPORATE SECRETARY

(Street)

NEW YORK NY 10001-2192

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
PFIZER INC [ PFE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Executive Vice President

3. Date of Earliest Transaction (Month/Day/Year)
03/03/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Appreciation Rights	$26.58	03/03/2026		A		194,883		03/03/2031(1)	03/03/2031(1)	Common Stock	194,883	$0.0000	194,883	D

Explanation of Responses:

1. The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant.

	/s/ Shanice A. Reid, by power of atty, for Alexandre de Germay	03/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Pfizer (PFE) report for Alexandre de Germay?

Pfizer reported that Executive Vice President Alexandre de Germay acquired 194,883 stock appreciation rights. These were granted as a derivative award, not an open-market share purchase, and increase his potential future equity-linked compensation in Pfizer common stock.

How many stock appreciation rights were granted to Alexandre de Germay at Pfizer (PFE)?

Alexandre de Germay received 194,883 stock appreciation rights. This entire amount was acquired in a single award transaction and represents a new grant of derivative securities tied to Pfizer common stock under his executive compensation.

When will Alexandre de Germay’s Pfizer (PFE) stock appreciation rights be settled?

The stock appreciation rights will be settled in Pfizer common stock on the fifth anniversary of the grant date. Settlement timing is fixed in the award terms, subject to the vesting requirements described in the transaction footnote.

Are there vesting conditions on Alexandre de Germay’s Pfizer (PFE) stock appreciation rights?

Yes. The filing states the stock appreciation rights are subject to certain vesting requirements. Only after meeting these conditions will they be settled in shares of Pfizer common stock on the fifth anniversary of the grant date.

Does Alexandre de Germay pay a price per share for the Pfizer (PFE) stock appreciation rights?

No purchase price is shown for this grant, with the transaction price per share reported as 0.0000. This indicates the stock appreciation rights were awarded as compensation rather than bought in the open market.

How is Alexandre de Germay’s ownership reflected after this Pfizer (PFE) award?

Following the transaction, total derivative securities from this award are listed as 194,883 stock appreciation rights held directly. These rights provide future share-settled value, subject to vesting and the five-year settlement schedule.